Pembrolizumab versus Ipilimumab in Advanced Melanoma
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...
Publications
2 shownSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rat...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 9,013
- Institution
- Université Paris-Sud
External Links
Identifiers
- ORCID
- 0000-0002-4642-5982
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.